The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.
 
Luke T. Nordquist
No Relationships to Disclose
 
Neal D. Shore
Research Funding - Innocrin Pharma (Inst)
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex
 
Shilpa Gupta
Consulting or Advisory Role - Genentech; pfizer; Seagen
 
William R. Berry
Research Funding - Innocrin Pharma (Inst)
 
Silke Gillessen
Consulting or Advisory Role - Astellas Pharma; Bayer; Curevac; Dendreon; Janssen-Cilag; Millennium; Novartis; Orion; pfizer; Sanofi
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
 
Glenn Liu
Stock and Other Ownership Interests - AIQ Solutions
Research Funding - Cellectar (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
Other Relationship - AIQ Solutions
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Eleni Efstathiou
Honoraria - Astellas Pharma; Janssen-Cilag; Sanofi; takeda
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Sanofi; Tokai Pharmaceuticals
Research Funding - Janssen-Cilag
Travel, Accommodations, Expenses - Sanofi
 
Mark T. Fleming
Research Funding - Innocrin Pharma (Inst)
 
Daniel J. George
Honoraria - Bayer; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; BIND Biosciences; Dendreon; Exelixis; GlaxoSmithKline; Innocrin Pharma; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Dendreon; Novartis; Sanofi
Research Funding - Acerta Pharma; Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Novartis; Pfizer; Sanofi
 
John C. Araujo
No Relationships to Disclose
 
Jingsong Zhang
Research Funding - Innocrin Pharma (Inst)
 
Michael R Kurman
Stock and Other Ownership Interests - Innocrin Pharma
Consulting or Advisory Role - Innocrin Pharma
 
Joel Robert Eisner
Employment - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
William R. Moore
Employment - Innocrin Pharma
Leadership - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
Patents, Royalties, Other Intellectual Property - Innocrin Pharma